Find research datasets worth reusing

opencc-zeroJul 2022View details →

Supplementary material 1 from: Yaseen Y, Kubba A, Shihab W, Tahtamouni L (2022) Synthesis, docking study, and structure-activity relationship of novel niflumic acid derivatives acting as anticancer agents by inhibiting VEGFR or EGFR tyrosine kinase activities. Pharmacia 69(3): 595-614. https://doi.org/10.3897/pharmacia.69.e86504

Figures S1, S2, Tables S1, S2

dryad28/100

Dataset for: Numerical simulations of sheared granular materials by 3D DEM for analyzing formation of internal structures and relationship between it and frictional behavior

<p>We conducted numerical simulations of sheared granular materials under normal stress by using 3D DEM method in order to analyze internal structures and relationship between their formation and frictional behavior. This dataset includes raw data for plotting figures in our article and run scripts and CAD files for simulations.</p>

opencc-zeroOct 2022View details →

opencc-by-4.0Jun 2024View details →

Models from "Applying Machine Learning to Characterize and Extrapolate the Relationship Between Seismic Structure and Surface Heat Flow"

Open the record for dataset details and reuse information.

Fig. 1 in Constituents promoting osteogenesis from the fruits of Psoralea corylifolia and their structure-activity relationship study

Fig. 1. Structures of 37 undescribed compounds.

Fig. 6 in Constituents promoting osteogenesis from the fruits of Psoralea corylifolia and their structure-activity relationship study

Fig. 6. SPR sensorgrams of eight compounds and E2 binding to ERβ at various concentration.

Fig. 2 in Constituents promoting osteogenesis from the fruits of Psoralea corylifolia and their structure-activity relationship study

Fig. 2. Selected HMBC (H → C) and 1H–1H COSY (H–H) correlations of undescribed compounds.

Fig. 3 in Constituents promoting osteogenesis from the fruits of Psoralea corylifolia and their structure-activity relationship study

Fig. 3. ORTEP drawing of compounds 1, 7, 8 and 33.

Fig. 14 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 14. The newly reported compounds of polymeric lignans.

Fig. 12 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 12. The newly reported compounds of seco-lignans.

Fig. 13 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 13. The newly reported compounds of norlignans.

Fig. 10 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 10. The newly reported compounds of benzofuran lignans.

Fig. 11 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 11. The newly reported compounds of oxyneolignans and non-oxyneolignans.

Fig. 5 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 5. The newly reported compounds of arylnaphthalenelactones lignans.

Fig. 6 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 6. The newly reported compounds of furofuran lignans.

Fig. 8 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 8. Basic skeletons of neolignans.

Fig. 3 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 3. The newly reported compounds of tetrahydrofuran lignans.

Fig. 1 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 1. Basic skeletons of lignans.

Fig. 9 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 9. The newly reported compounds of biphenyl lignans.

Fig. 7 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 7. The newly reported compounds of dibenzocyclooctene lignans.

Fig. 4 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 4. The newly reported compounds of arylnaphthalene lignans.